Phase 3 trials have demonstrated a benefit from adjuvant radiation therapy (ART) for men who have adverse factors at radical prostatectomy (RP). However, some patients have a high risk of progression despite ART. The role of systemic therapy with ART in this high-risk group remains to be defined. METHODS: Patients who had either a post-RP prostate-specific antigen (PSA) nadir > 0.2 ng/mL and a Gleason score 7 or a PSA nadir 0.2 ng/mL, a Gleason score 8, and a pathologic tumor (pT) classification pT3 received 6 months of androgen-deprivation therapy (ADT) plus radiotherapy and 6 cycles of docetaxel. The primary objective was to assess whether the addition of ADT and docetaxel to ART resulted in a freedom from progression (FFP) rate 70% compared with an expected rate of 50%. Multivariate logistic and Cox regression analyses were used to model associations between factors and outcomes. RESULTS: In total, 74 patients were enrolled. The median follow-up was 4.4 years. The pathologic tumor classification was pT2 in 4% of patients, pT3 in 95%, and pT4 in 1%. The Gleason score was 7 in 18% of patients and 8 in 82%. Post-RP PSA levels were 0.2 ng/mL in 53% of patients and >0.2 ng/mL in 47%. The 3-year FFP rate was 73% (95% confidence interval, 61%-83%), and the 3-year cumulative incidence of biochemical, distant, and local failure was 26%, 7%, and 0%, respectively. In multivariate models, postprostatectomy PSA nadir was associated with 3-year FFP, Gleason score, and PSA with biochemical failure. Grade 3 and 4 neutropenia was common; however, only 3 episodes of febrile neutropenia occurred. Late toxicities were not impacted by the addition of systemic therapy. CONCLUSIONS: Combined ADT, docetaxel, and ART for men with high-risk prostate cancer after prostatectomy exceeded the prespecified study endpoint of 70% 3-year FFP. Phase 3 trials assessing combined local and systemic therapies for these high-risk patients are warranted. Cancer 2017;123:2489-96.
INTRODUCTION
Radical prostatectomy (RP) is common treatment for prostate cancer. Although a majority of patients with favorable risk features do well, those with high-risk features have a substantial risk of disease recurrence. Patients with persistently elevated prostate-specific antigen (PSA) levels postprostatectomy or who experience biochemical failure within 3 years of surgery have a significantly increased risk of death from prostate cancer. 1 Patients commonly receive radiation therapy (RT) after prostatectomy. Randomized trials of adjuvant RT (ART) have demonstrated an improvement in progression-free survival and, with long-term follow-up, an overall survival advantage. [2] [3] [4] Despite this overall benefit, 50% of patients with pT3 and Gleason 8 disease or Gleason 7 and a PSA nadir >0.2 ng/mL experienced treatment failure within 3 years. Patients in this subset fail despite receipt of both surgery and RT and thus are expected to be at greater risk of death from prostate cancer than those who fail only surgery.
Optimal therapies remain to be defined for patients who have high-risk disease despite the receipt of RT in the postprostatectomy setting. Standard care for high-risk patients who receive primary RT includes androgen-deprivation Protocol approval was received from the institutional review board at each site. Informed consent was obtained from patients before participation. Eligible patients had prostatic adenocarcinoma with either a Gleason score 7 at prostatectomy and a PSA nadir >0.2 ng/mL or a Gleason score 8 at prostatectomy, a PSA nadir 0.2 ng/mL, and a pathologic tumor (pT) classification pT3a. Patients were enrolled within one year of RP. Subjects had no lymph node or distant metastases determined by bone scan and magnetic resonance imaging or computer tomography of the pelvis.
A Zubrod performance status 1 was required. A PSA level was obtained 6 weeks before registration. Absolute neutrophil count 2000 cells/mm 3 , platelet count 100,000 cells/mm 3 , hemoglobin 8.0 g/dL, alanine and aspartate transaminase 1.5 times, alkaline phosphatase 2.5 times, and total bilirubin 1.2 times the institutional upper normal limit were required.
Treatment
ADT, including a luteinizing hormone-releasing hormone agonist and a nonsteroidal antiandrogen (bicalutamide 50 mg daily) were administered for 6 months beginning 8 weeks before RT.
RT was administered with either 3-dimenisonal conformal RT (3DCRT) or intensity-modulated RT (IMRT) using energies 6 MV. The total dose to the prostate bed was 6660 6 180 centigray (cGy), including an initial pelvic field of 4500 cGy using daily fractions of 180 cGy. Pelvic fields included a superior border extending at a minimum to the bottom of the sacroiliac joint and at most superiorly to the lumbar 5-sacral 1 interspace. Seminal vesicle remnants if present received a minimum of 5040 cGy and could receive full dose at the discretion of the treating physician.
Patients received docetaxel 3 to 6 weeks after completion of RT and 6 cycles of 75 mg/m 2 intravenously every 3 weeks. Premedication with dexamethasone was required. If granulocytes were 1500 cells/mm 3 or platelets were 100,000 cells/mm 3 , as measured within 1 day of docetaxel administration, then treatment was held and counts were repeated weekly with modification of subsequent docetaxel doses. If neutropenia/thrombocytopenia did not resolve to a point that allowed a patient to receive docetaxel by 15 days of scheduled chemotherapy, then chemotherapy was discontinued. Docetaxel was also modified or held because of abnormal liver function tests. The dose was reduced by 25% for grade 2 neuropathy without treatment delay or was discontinued for grade 3 neuropathy.
Follow-Up
Follow-up assessments occurred every 3 months for 2 years, every 6 months for 3 more years, and annually thereafter. The PSA level was obtained at each visit. PSA 0.4 ng/mL was verified with a repeat level to confirm progression. Bone scans and computed tomography or magnetic resonance imaging studies were recommended at least annually after PSA progression to determine rates of metastatic progression.
Statistical Design and Analysis
The primary endpoint was FFP, with failure defined as PSA 0.4 ng/mL after the end of RT confirmed by a second higher PSA, nonprotocol hormones, locoregional progression, distant metastasis, or death within 3 years after registration. According to Southwest Oncology Group (SWOG) Study 8794, the expected FFP rate was 50% for patients who underwent prostatectomy and also received RT. The experimental therapy was to be deemed effective if the FFP rate was 70%. According to the Fleming multiple testing procedure with 3 stages, 69 patients were required to test the null hypothesis (FFP 50%) against the alternative (FFP 70%) with 90% power and a significance level .025. Allowing for 10% patient ineligibility or nonevaluability, the total sample size was 76. At final analysis, if 44 of 69 patients had no FFP event (ie, if they were alive and progression free), then the null hypothesis would be rejected, and we would conclude that the FFP rate was 0.7. The 95% confidence interval (CI) for the FFP rate was calculated using the Clopper-Pearson method.
Secondary endpoints included FFP (at any time), locoregional progression, distant metastases, biochemical failure, overall survival, prostate cancer death, nonprostate-cancer death, and acute (within 90 days of treatment end, 3 weeks after the last planned docetaxel Original Article dose) and late (91 days after treatment end) treatmentrelated (definitely, probably, or possibly related to treatment) adverse events. Adverse events were scored using Common Terminology Criteria for Adverse Events, version 3.0. The FFP and survival rates were estimated using the Kaplan-Meier method, and all others were estimated using the cumulative incidence method, with death before failure as a competing risk. Age, Gleason score, PSA, tumor classification, lymph node status, and surgical margin status were correlated with outcomes by using logistic or Cox regression.
RESULTS
Eighty patients from 33 sites were enrolled between April 2008 and September 2010, of which 74 who met eligibility requirements were included in the analysis. Details of patient enrollment are provided in Figure 1 , and patient characteristics are listed in Table 1 . The post-RP PSA level was 0.2 ng/mL in 39 patients (52.7%) and >0.2 ng/mL in 35 patients (47.3%). Among men who had post-RP PSA levels > 0.2 ng/mL, the median level was 0.60 ng/mL (interquartile range, 0.40-2.49 ng/mL). Surgical margins were positive in 43 patients (58.1%).
FFP in the First 3 Years
Because the final analysis included 74 patients, 46 patients who had no FFP event (ie, they were alive and progression free) were required to reject the null hypothesis (rather than 44 patients). Fifty-four of 74 patients had no FFP event, so the null hypothesis was rejected. The estimated FFP rate was 73% (95% CI, 61.4%-82.6%). A post-RP PSA level > 0.2 ng/mL was associated with an increased risk of failure in univariate analysis (odds ratio, 10.94; 95% CI, 2.68-65.81; P < .001) and multivariate analysis (odds ratio, 16.27; 95% CI, 3.51-108.17; P < .001) adjusted for Gleason score (8-10 vs 7).
Time-to-Event Outcomes
The median follow-up among surviving patients was 4.4 years (range, 3.3-5.6 years). The 3-year FFP rate was 73% (95% CI, 62.9%-83.1%) (Fig. 2) . Twenty-six patients experienced treatment failure, including 20 within 3 years. Biochemical failure was the first event noted in 24 patients (92.3%), including 2 (7.7%) who presented with metastases as the initial sign of treatment failure. Eleven patients developed metastases. Three deaths occurred, including 2 from prostate cancer. The 3-year estimates are presented in Table 2 . Gleason scores from 8 to 10 and post-RP PSA levels > 0.2 ng/mL were associated with an increased risk of failure for the endpoints FFP and biochemical failure in multivariate analysis, but only PSA levels >0.2 ng/mL were associated with an increased risk in univariate analysis (Table 3) . Discrepant results for Gleason score between univariate and bivariate analyses were likely because of the eligibility criteria, in which patients who had a Gleason score of 7 were only eligible if they had a PSA level >0.2 ng/mL. In univariate analysis, post-RP PSA levels > 0.2 ng/mL were also associated with an increased risk of distant metastasis (hazard ratio, 12.62; 95% CI, 1.61-98.65; P 5 .02).
Treatment Delivery
Sixty-six of 74 patients (89.2%) were scored by study chairs according to protocol or with acceptable variation for RT. Seventy of 74 patients (94.6%) were scored according to protocol for chemotherapy, and 61 of 70 had no modifications or delays. For RT, 89.2% of patients received IMRT, 9.5% received 3DCRT, and 1 received no RT. All 73 patients who started RT received 66.6 6 1.8 gray. Sixty-seven of 74 patients (90.5%) received 6 cycles of docetaxel, and 1 patient did not receive any docetaxel. All patients received luteinizing hormone-releasing hormone agonist, and all but 1 received oral antiandrogen.
Adverse Events
Chemotherapy side effects were common but manageable and did not increase long-term toxicity. Thirty-five patients (47.3%) experienced at least 1 grade 4 treatmentrelated adverse event at any time, and an additional 23 (31.1%) experienced at least 1 grade 3 treatment-related adverse event at any time. Acute treatment-related adverse events are summarized in Table 4 . The most common acute toxicities were hematologic, including grade 3 and 4 neutropenia (16.2% and 40.5% of patients, respectively), leukopenia (35.1% and 13.5%, respectively) and lymphopenia (13.5% and 2.7%, respectively). However, only 4.1% of patients developed febrile neutropenia, and infection was limited to a single episode of grade 3 urinary tract infection. Grade 2 and 3 peripheral neuropathy occurred in 13.5% and 1.4% of patients, respectively. Late treatment-related toxicities included 6 episodes (8.1%) of various grade 3 toxicities and 2 episodes (2.7%) of grade 4 urinary incontinence (Table 5 ). The 2-year cumulative incidence of grade 3 and 4 late toxicity was 8.1% (95% CI, 3.3%-15.8%). 2-4 All 3 of those randomized studies reported a benefit in progression-free survival; and, in the SWOG 8794 trial with long-term follow-up, an overall survival benefit was noted.
DISCUSSION
Postprostatectomy ART will benefit many men; however, a review of studies that assessed postprostatectomy RT revealed subsets of patients at high risk of failure after both surgery and RT. In a large series from Johns Hopkins, men who experienced treatment failure within Figure 1 . This is the NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0621 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. ANC indicates absolute neutrophil count; Gy, gray; LRHR, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; RT, radiation therapy.
3 years of prostatectomy had a 15-year risk of prostate cancer-specific mortality of 59% compared with 13% who experienced treatment failure after a longer postoperative period. In designing the current study, a subgroup of patients from the SWOG 8794 study was identified that, on average, had a 50% risk of failure by 3 years despite the addition of ART. Because these patients are at high risk of failing 2 local therapies, the current study was designed to assess the potential benefit of adding docetaxel and ADT to RT in this high-risk population.
Although the roles of ADT and chemotherapy in combination with postoperative RT have yet to be defined, a survival benefit with ADT and a potential benefit with docetaxel in other high-risk settings have been noted. The addition of ADT to primary RT is standard in the setting of high-risk prostate cancer and has an established survival benefit. Phase 3 trials have also revealed a survival benefit with docetaxel in metastatic prostate cancer, initially in the setting of castration-resistant disease 6, 7 ; and, more recently, a large survival benefit was noted in the CHAARTED study when docetaxel was received at the initiation of ADT for newly diagnosed, metastatic castration-sensitive disease. 8 The STAMPEDE trial demonstrated a benefit from docetaxel in metastatic disease and its potential utility in the locally advanced setting, and initial results from Radiation Therapy Oncology Group (RTOG) study 0521 indicate there may be a survival benefit in the primary treatment of high-risk patients. 9, 10 Benefits observed with the use of docetaxel at earlier points in the course of prostate cancer support the investigation of its use in high-risk patients postprostatectomy who are without frank evidence of metastases but are likely to fail despite local therapy. The findings of the currently study support the hypothesis that the use of systemic therapy benefits men without established metastatic disease who nevertheless are at high risk of local treatment failure despite both RP and postoperative RT. The 3-year FFP rate was 73% compared with a projected rate of 50% observed among patients who had high-risk features in the adjuvant radiation arm of SWOG 8794. Although comparisons between studies must be viewed with caution, on review of patient characteristics and known prognostic factors, men enrolled on the current study appeared to be a higher risk cohort compared with the SWOG historic controls. In the current study, 82% of patients had Gleason scores from 8 to 10 versus 9% in the historic control series. PSA failed to nadir to 0.2 ng/mL in 47% of patients in the current study versus 36% of patients in SWOG 8794. Fifty-seven percent of patients in the current study had seminal vesicle involvement versus 31% in SWOG 8794, and fewer had positive margins. All of these factors have been associated with a greater risk of treatment failure in prior studies, including SWOG 8794. 11 Furthermore, both PSA nadir and Gleason score were associated with an increased risk of treatment failure on multivariate analysis in the current study, suggesting that the benefit from adding systemic therapy in these veryhigh-risk patients may exceed the estimated 23%.
Additional study of docetaxel in high-risk patients postprostatectomy is indicated noting both the potential benefits and toxicities. High rates of hematologic toxicities, including grade 3 and 4 neutropenia and leukopenia, occurred on the current study. These rates appear to be higher than those reported previously in series that assessed the use of docetaxel in treatment for metastatic prostate cancer, likely reflecting the initiation of docetaxel Post-RP Radiation, ADT, and Docetaxel/Hurwitz et al
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3 to 6 weeks after completion of pelvic RT. 7, [11] [12] [13] The impact of the timing of docetaxel initiation after RT on hematologic toxicities warrants further investigation. Although the concurrent receipt of docetaxel and RT may have sensitizing effects, as commonly observed in the treatment of other malignancies, the rates of hematologic toxicity noted in the current study support the sequential use of pelvic RT and docetaxel in this clinical setting. It is important to note that, although the rates of these laboratory toxicities were high, rates of febrile neutropenia and infection were similar to these in previously reported series. 7, 12 Rates of other toxicities commonly associated with docetaxel, including peripheral neuropathy, were in line with the expected rates. 13 It is noteworthy that receipt of docetaxel and ADT in the current study was not associated with increased long-term toxicities, including the exacerbation of genitourinary and gastrointestinal side effects commonly observed with RT. 4, 14 It is important to note limitations of the current study. Because of the nonrandomized phase 2 design, the impact of each intervention, including RT, ADT, and docetaxel, on improving the FFP rate compared with historic controls remains to be defined. Improved surgical techniques and changes in Gleason grading since the completion of SWOG 8794 might have accounted for some of the benefit observed on NRG Oncology/RTOG 0621. Original Article
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Cancer However, this concern is significantly mitigated by the comparatively higher risk factors among the men enrolled on NRG Oncology/RTOG 0621, including more patients with persistently detectable postoperative PSA. It is unlikely that changes in Gleason grading over time can account for the large discrepancy in the numbers of men with high-risk disease (Gleason 8) between studies. The current study also differed from prior phase 3 trials of ART in the use of an initial pelvic field and a prescribed dose of 6660 cGy compared with the 6000 to 6400 cGy doses used in previous phase 3 trials, including SWOG 8794, which was the comparator study for the current series. The results from a DART01/05 trial indicating benefit to extended ADT in addition to dose-escalated RT as primary treatment for high-risk patients suggests that the benefit observed in the current study is unlikely because pelvic RT was used along with slightly higher doses, as now commonly used. 15 The use of ADT may also provide a lead-time bias in defining treatment failure because of the time required for testosterone recovery. Ultimately, the contribution of docetaxel and ADT and whether extended duration of ADT would provide further benefit are questions that only a phase 3 trial can definitively answer.
The optimal approach to managing high-risk patients remains an important question to be answered in the postprostatectomy setting. The NRG Oncology/ RTOG 0621 study has revealed a very-high-risk subset of patients postprostatectomy at near-term risk of disease progression even with combined local and systemic therapy. The results of the current study strongly support further investigations into integrating systemic therapies, including both ADT and chemotherapy, with postoperative RT in this patient population.
Conclusions
The addition of docetaxel and ADT to ART for men at high risk of failure despite receiving both surgery and RT resulted in a significant improvement in 3-year FFP compared with historic controls who received RT alone. Although past randomized trials have proven the efficacy of ART in selected subsets of men after RP, the individual contribution of hormone therapy and docetaxel in this setting will require additional, appropriately designed, prospective randomized studies.
